share_log

Do Jiangsu Yuyue Medical Equipment & Supply's (SZSE:002223) Earnings Warrant Your Attention?

Do Jiangsu Yuyue Medical Equipment & Supply's (SZSE:002223) Earnings Warrant Your Attention?

江蘇魚躍醫療器材及用品(深圳證券交易所:002223)的收益值得您關注嗎?
Simply Wall St ·  2023/12/27 17:39

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.

對於初學者來說,收購一家向投資者講述好故事的公司似乎是個好主意(也是一個令人興奮的前景),即使該公司目前缺乏收入和利潤記錄。但現實是,當一家公司每年虧損足夠長的時間時,其投資者通常會承擔虧損的份額。虧損公司可以像資本海綿一樣行事,因此投資者應謹慎行事,不要浪費好錢。

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Jiangsu Yuyue Medical Equipment & Supply (SZSE:002223). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.

因此,如果這種高風險和高回報的想法不適合,那麼你可能會對盈利、成長中的公司更感興趣,例如江蘇魚躍醫療器械有限公司(SZSE:002223)。現在,這並不是說該公司提供了最好的投資機會,但盈利能力是業務成功的關鍵因素。

Check out our latest analysis for Jiangsu Yuyue Medical Equipment & Supply

查看我們對江蘇魚躍醫療設備及用品的最新分析

Jiangsu Yuyue Medical Equipment & Supply's Earnings Per Share Are Growing

江蘇魚躍醫療器材供應的每股收益正在增長

If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. It certainly is nice to see that Jiangsu Yuyue Medical Equipment & Supply has managed to grow EPS by 20% per year over three years. If growth like this continues on into the future, then shareholders will have plenty to smile about.

如果一家公司能夠在足夠長的時間內保持每股收益(EPS)的增長,那麼其股價最終應該會緊隨其後。因此,有很多投資者喜歡購買每股收益不斷增長的公司的股票。很高興看到江蘇魚躍醫療設備有限公司在三年內設法將每股收益增長20%。如果這樣的增長持續到未來,那麼股東們將有很多值得微笑的地方。

Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. The music to the ears of Jiangsu Yuyue Medical Equipment & Supply shareholders is that EBIT margins have grown from 17% to 25% in the last 12 months and revenues are on an upwards trend as well. Both of which are great metrics to check off for potential growth.

仔細考慮收入增長和息稅前收益(EBIT)利潤率有助於爲近期利潤增長的可持續性提供信息。令江蘇魚躍醫療設備及供應股東聽到的消息是,在過去的12個月中,息稅前利潤率從17%增長到25%,收入也呈上升趨勢。這兩個指標都是衡量潛在增長的好指標。

The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.

下圖顯示了該公司的收入和收入隨着時間的推移是如何發展的。要了解更多細節,請點擊圖片。

earnings-and-revenue-history
SZSE:002223 Earnings and Revenue History December 27th 2023
SZSE: 002223 2023 年 12 月 27 日的收益和收入歷史記錄

Of course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for Jiangsu Yuyue Medical Equipment & Supply.

當然,訣竅是找到未來表現最好的股票,而不是過去的股票。當然,你可以根據過去的表現來看待你的看法,但你可能還需要查看這張專業分析師對江蘇魚躍醫療設備及供應每股收益預測的互動圖表。

Are Jiangsu Yuyue Medical Equipment & Supply Insiders Aligned With All Shareholders?

江蘇魚躍醫療設備及供應業內部人士是否與所有股東保持一致?

It should give investors a sense of security owning shares in a company if insiders also own shares, creating a close alignment their interests. Jiangsu Yuyue Medical Equipment & Supply followers will find comfort in knowing that insiders have a significant amount of capital that aligns their best interests with the wider shareholder group. We note that their impressive stake in the company is worth CN¥6.2b. That equates to 18% of the company, making insiders powerful and aligned with other shareholders. Looking very optimistic for investors.

如果內部人士也擁有股份,這應該會給投資者一種擁有公司股份的安全感,從而使他們的利益緊密一致。江蘇魚躍醫療設備與供應的追隨者會感到欣慰的是,內部人士擁有大量資金,可以使他們的最大利益與更廣泛的股東群體保持一致。我們注意到,他們在該公司的可觀股份價值62億元人民幣。這相當於公司18%的股份,使內部人士變得強大並與其他股東保持一致。對投資者來說看起來非常樂觀。

Does Jiangsu Yuyue Medical Equipment & Supply Deserve A Spot On Your Watchlist?

江蘇魚躍醫療設備及用品值得在您的關注清單上佔有一席之地嗎?

You can't deny that Jiangsu Yuyue Medical Equipment & Supply has grown its earnings per share at a very impressive rate. That's attractive. With EPS growth rates like that, it's hardly surprising to see company higher-ups place confidence in the company through continuing to hold a significant investment. On the balance of its merits, solid EPS growth and company insiders who are aligned with the shareholders would indicate a business that is worthy of further research. Before you take the next step you should know about the 3 warning signs for Jiangsu Yuyue Medical Equipment & Supply (1 is a bit unpleasant!) that we have uncovered.

你不能否認江蘇魚躍醫療設備及供應的每股收益以非常可觀的速度增長。這很有吸引力。在每股收益增長率如此之高的情況下,看到公司高層通過繼續持有大量投資對公司充滿信心也就不足爲奇了。從優點來看,穩健的每股收益增長以及與股東保持一致的公司內部人士將表明該業務值得進一步研究。在你採取下一步行動之前,你應該了解江蘇魚躍醫療設備及用品的3個警告標誌(1個有點不愉快!)這是我們發現的。

While opting for stocks without growing earnings and absent insider buying can yield results, for investors valuing these key metrics, here is a carefully selected list of companies in CN with promising growth potential and insider confidence.

雖然選擇收益不增長且沒有內幕買盤的股票可以產生業績,但對於估值這些關鍵指標的投資者來說,以下是精心挑選的具有良好增長潛力和內部信心的內地公司名單。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

請注意,本文中討論的內幕交易是指相關司法管轄區內應報告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論